92 related articles for article (PubMed ID: 20597624)
1. New findings offer insight into resistance to breast cancer therapy.
Womens Health (Lond); 2010 Jul; 6(4):493. PubMed ID: 20597624
[No Abstract] [Full Text] [Related]
2. Interaction of developmental transcription factor HOXC11 with steroid receptor coactivator SRC-1 mediates resistance to endocrine therapy in breast cancer [corrected].
McIlroy M; McCartan D; Early S; O Gaora P; Pennington S; Hill AD; Young LS
Cancer Res; 2010 Feb; 70(4):1585-94. PubMed ID: 20145129
[TBL] [Abstract][Full Text] [Related]
3. S100 protein in breast tumor.
Li F; Men X; Zhang W
Indian J Cancer; 2014 Mar; 51 Suppl 3():e67-71. PubMed ID: 25818737
[TBL] [Abstract][Full Text] [Related]
4. De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer.
Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
Pharmacogenomics; 2015; 16(12):1411-26. PubMed ID: 26257318
[TBL] [Abstract][Full Text] [Related]
5. The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers.
Légaré S; Cavallone L; Mamo A; Chabot C; Sirois I; Magliocco A; Klimowicz A; Tonin PN; Buchanan M; Keilty D; Hassan S; Laperrière D; Mader S; Aleynikova O; Basik M
Cancer Res; 2015 Oct; 75(20):4351-63. PubMed ID: 26297734
[TBL] [Abstract][Full Text] [Related]
6. Co-expression of S100A14 and S100A16 correlates with a poor prognosis in human breast cancer and promotes cancer cell invasion.
Tanaka M; Ichikawa-Tomikawa N; Shishito N; Nishiura K; Miura T; Hozumi A; Chiba H; Yoshida S; Ohtake T; Sugino T
BMC Cancer; 2015 Feb; 15():53. PubMed ID: 25884418
[TBL] [Abstract][Full Text] [Related]
7. Genomic testing for sensitivity of breast cancer to hormonal therapy.
Symmans WF
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1954-5. PubMed ID: 16609001
[No Abstract] [Full Text] [Related]
8. Evaluating an ER Degrader for Breast Cancer.
Cancer Discov; 2015 Jul; 5(7):OF15. PubMed ID: 25956960
[No Abstract] [Full Text] [Related]
9. Changing Treatment Paradigms in Metastatic Breast Cancer: Lessons Learned.
Santa-Maria CA; Gradishar WJ
JAMA Oncol; 2015 Jul; 1(4):528-34; quiz 549. PubMed ID: 26181262
[TBL] [Abstract][Full Text] [Related]
10. Intrinsic resistance to chemotherapy in breast cancer.
Moulder S
Womens Health (Lond); 2010 Nov; 6(6):821-30. PubMed ID: 21118040
[TBL] [Abstract][Full Text] [Related]
11. [Proteomics and breast cancer: new perspectives and limitations].
Hondermarck H
Pathol Biol (Paris); 2006 May; 54(4):194-8. PubMed ID: 16632259
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?
Chandarlapaty S; Modi S
J Clin Oncol; 2011 Aug; 29(23):3111-3. PubMed ID: 21730267
[No Abstract] [Full Text] [Related]
13. Unraveling the complexity of endocrine resistance in breast cancer by functional genomics.
Swanton C; Downward J
Cancer Cell; 2008 Feb; 13(2):83-5. PubMed ID: 18242507
[TBL] [Abstract][Full Text] [Related]
14. Test may help predict chemotherapy response and survival in breast cancer.
Printz C
Cancer; 2011 Oct; 117(19):4339. PubMed ID: 21928334
[No Abstract] [Full Text] [Related]
15. Molecular markers of multiple drug resistance in breast cancer.
O'Driscoll L; Clynes M
Chemotherapy; 2006; 52(3):125-9. PubMed ID: 16612055
[TBL] [Abstract][Full Text] [Related]
16. [Trastuzumab in the breast cancer treatment: efficacy and resistance mechanisms].
Grell P; Svoboda M; Simícková M; Fabian P; Vyzula R
Klin Onkol; 2009; 22(2):45-51. PubMed ID: 19522373
[TBL] [Abstract][Full Text] [Related]
17. Replication association analysis of S100B and cognitive ageing.
Houlihan LM; Harris SE; Deary IJ; Starr JM
Psychiatr Genet; 2010 Jun; 20(3):133-4. PubMed ID: 20473040
[No Abstract] [Full Text] [Related]
18. Can strategies targeting cleaved MUC1 overcome resistance to trastuzumab?
Araki K; Pegram M
Breast Cancer Res Treat; 2011 Jun; 127(2):589-90. PubMed ID: 19834800
[No Abstract] [Full Text] [Related]
19. Breast cancer and genomic testing.
Liedtke C; Kolberg HC
Br J Surg; 2017 Jun; 104(7):799-801. PubMed ID: 28300277
[No Abstract] [Full Text] [Related]
20. Management of patients with HER2-positive metastatic breast cancer: is there an optimal sequence of HER2-directed approaches?
Zelnak AB; Wisinski KB
Cancer; 2015 Jan; 121(1):17-24. PubMed ID: 25056442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
